{
    "organizations": [],
    "uuid": "698f06f387d254dc954cf0f92debf0f9ce720bf2",
    "author": "Reuters Editorial",
    "url": "https://www.reuters.com/article/brief-astrazeneca-says-us-fda-approves-t/brief-astrazeneca-says-u-s-fda-approves-tagrisso-as-1st-line-treatment-for-egfr-mutated-non-small-cell-lung-cancer-idUSFWN1RV105",
    "ord_in_thread": 0,
    "title": "BRIEF-Astrazeneca says U.S. FDA Approves Tagrisso As 1st-Line Treatment For EGFR-Mutated Non-Small Cell Lung Cancer",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "April 18 (Reuters) - AstraZeneca PLC:\n* US FDA APPROVES TAGRISSO AS 1ST-LINE TREATMENT FOR EGFR-MUTATED NON-SMALL CELL LUNG CANCER Further company coverage:\n ",
    "published": "2018-04-19T06:46:00.000+03:00",
    "crawled": "2018-04-19T14:43:05.003+03:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "april",
        "reuters",
        "astrazeneca",
        "plc",
        "u",
        "fda",
        "approves",
        "tagrisso",
        "treatment",
        "cell",
        "lung",
        "cancer",
        "company",
        "coverage"
    ]
}